Their study, "Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics" was published in the Journal of Alzheimer's Disease.
Investigators found salivary molecules hold promise as reliable diagnostic biomarkers.
The study exemplifies the quest by scientists to combat Alzheimer's disease, a degenerative brain disorder with no cure and few reliable diagnostic tests. In the United States, Alzheimer's is a health epidemic affecting more than 5 million Americans. Investigators seek to develop valid and reliable biomarkers, diagnosing the disease in its earliest stages before brain damage occurs and dementia begins.
Researcher Stewart Graham, Ph.D., said, "We used metabolomics, a newer technique to study molecules involved in metabolism. Our goal was to find unique patterns of molecules in the saliva of our study participants that could be used to diagnose Alzheimer's disease in the earliest stages, when treatment is considered most effective. Presently, therapies for Alzheimer's are initiated only after a patient is diagnosed and treatments offer modest benefits."
Metabolomics is used in medicine and biology for the study of living organisms. It measures large numbers of naturally occurring small molecules, called metabolites, present in the blood, saliva and tissues. The pattern or fingerprint of metabolites in the biological sample can be used to learn about the health of the organism.
Alzheimer's disease is a type of dementia affecting a person's ability to think, communicate and function. It greatly impacts their relationships, their independence and lifestyle. The condition's toll not only affects millions of Americans, but in 2017, it could cost the nation $259 billion.